Integra LifeSciences Holdings Corporation IART
Set alert
At close · Nov 2
After hours · Nov 2, 7:46 PM ET
- YTD
- +9.58%
- 1 year
- +13.32%
- Open
- 12.98
- Prev close
- 12.75
- Mkt cap
- 1.06B
- Vol
- 1.51M
- Avg vol
- 950.56K
- EPS
- 0.18
- P/E
- 75.61
- Div yield
- 0.00%
More statistics
- Low
- 12.98
- High
- 13.97
- Forward P/E
- 5.70
- Beta
- 1.28
- Short ratio
- 6.30
- Inst. own
- 98.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 14.84
- 200-d avg
- 14.07
- 1y target
- 15.67
News
3 days ago globenewswire.com
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026…
4 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation ("Integra" or the "Company") (NASDAQ: IART). Such…
6 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such…
-
6 days ago benzinga.com
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.
-
1 week ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
1 week ago seekingalpha.com
Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting
Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to…
1 week ago gurufocus.com
Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. [url="]Glancy
1 week ago businesswire.com
Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke &…
1 week ago businesswire.com
Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices…
-
1 week ago benzinga.com
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
-
1 week ago benzinga.com
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.
1 week ago businesswire.com
Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Integra LifeSciences Holdings Corporation ("Integra" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz…
-
1 week ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.
-
1 week ago benzinga.com
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.
-
1 week ago benzinga.com
JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
1 week ago benzinga.com
Integra LifeSciences' $2.1B Refinancing Merits A Closer Look
Integra LifeSciences Holdings Corporation (NASDAQ:IART) completed a $2.1 billion refinancing on October 19, 2026. Its revolving credit commitment fell $700 million, from $1.3 billion to $600 million,…
1 week ago newsfilecorp.com
Integra LifeSciences Holdings Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your IART Investments
New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Integra LifeSciences Holdings Corporation ("Integra" or the…
1 week ago seekingalpha.com
Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript
1 week ago fool.com
Integra: 3 Key Takeaways for Long-Term Investors
Operating cash flow hit a record even as the company navigates supply disruptions, a sign of underlying business resilience.
1 week ago marketbeat.com
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
Integra LifeSciences NASDAQ: IART reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue…
1 week ago zacks.com
Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
1 week ago benzinga.com
Integra Lifesciences Q3 2026 Earnings Call Transcript
Integra Lifesciences (NASDAQ:IART) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
1 week ago zacks.com
Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.54 per share a year ago.
-
1 week ago benzinga.com
Integra Lifesciences Q3 Adj. EPS $0.59 Beats $0.56 Estimate, Sales $411.182M Miss $414.120M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.56 by 5.36 percent. This is a 9.26 percent increase over earnings of…
-
1 week ago benzinga.com
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.30-$2.40 vs $2.42 Est; Affirms FY2026 Sales Guidance of $1.634B-$1.654B vs $1.661B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.30-$2.40 to $2.30-$2.40 vs $2.42 analyst estimate. Affirms FY2026 sales outlook from $1.634 billion-$1.654 billion to $1.634…
-
1 week ago benzinga.com
Integra Lifesciences Sees Q4 Adj EPS $0.61-$0.71 vs $0.76 Est; Sees Sales $413.000M-$433.000M vs $436.772M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q4 Adj EPS of $0.61-$0.71 vs $0.76 analyst estimate. sees sales of $413.000 million-$433.000 million vs $436.772 million analyst estimate.
1 week ago globenewswire.com
Integra LifeSciences Reports Third Quarter 2026 Financial Results
PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the…
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
2 weeks ago globenewswire.com
Integra Announces Completion of Refinancing Transactions
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal…
2 weeks ago globenewswire.com
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026…
-
2 weeks ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.
2 weeks ago businesswire.com
INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 21.2% Share Drop
NEW YORK--(BUSINESS WIRE)---- $IART #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Integra LifeSciences Holdings Corporation (“Integra”…
3 weeks ago defenseworld.net
Integra LifeSciences (NASDAQ:IART) & Precision Optics (NASDAQ:POCI) Critical Review
Precision Optics (NASDAQ: POCI - Get Free Report) and Integra LifeSciences (NASDAQ: IART - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will…
3 weeks ago defenseworld.net
Integra LifeSciences (NASDAQ: IART) prices $450 million notes to refinance debt
What happened Integra LifeSciences Holdings Corporation (NASDAQ: IART) in Princeton, N.J., priced $450 million of 9.500% senior secured notes due 2033 on October 9, 2026. The notes will be senior…
4 weeks ago benzinga.com
Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook
Integra LifeSciences cut its 2026 financial guidance after a July flood disrupted its Cincinnati facility and negatively impacted revenue.
-
4 weeks ago benzinga.com
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.
1 month ago benzinga.com
Crude Oil Down Over 1%; US Factory Orders Edge Higher In August
U.S. stocks rose Friday, led by Nasdaq (+1.27%), despite weak jobs data. Factory orders edged up; oil and gold fell. Alpha Modus surged 213%.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock…
-
1 month ago benzinga.com
Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B
Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its…
-
1 month ago benzinga.com
Integra LifeSciences Enrolls 100th Participant In Its AERA Pediatric Registry Observational Registry
Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter…
-
3 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.
-
3 months ago benzinga.com
Integra Lifesciences Sees Q3 Adj EPS $0.53-$0.61 vs $0.56 Est; Sees Sales $410.000M-$425.000M vs $418.100M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.53-$0.61 vs $0.56 analyst estimate. sees sales of $410.000 million-$425.000 million vs $418.100 million analyst estimate.
-
3 months ago benzinga.com
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.654B-$1.695B vs $1.676B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654…
-
3 months ago benzinga.com
Integra Lifesciences Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $418.761M Beat $418.647M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 24.44 percent increase over earnings…
-
3 months ago benzinga.com
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.
-
3 months ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.
-
3 months ago benzinga.com
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19
BMO Capital analyst Vik Chopra initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Market Perform rating and announces Price Target of $19.
-
3 months ago benzinga.com
Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and raises the price target from $16 to $19.
-
6 months ago benzinga.com
Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $11
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and raises the price target from $9 to $11.
-
6 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $15
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $12 to $15.